Visit the original URL
36 Krypton learned that the National Health and Medical Commission issued the “Diagnosis and Treatment Plan for Severe Cases of New Coronavirus Infection (Trial Version 4)”. The plan proposes that the combined packaging of Naimatevir/ritonavir tablets, Azivudine tablets and monogravir capsules: the combined packaging of Naimatevir/ritonavir tablets is used for mild cases within 5 days of onset. , medium-sized adult patients with high-risk factors for progression to severe disease. Azvudine tablets are used for adult patients with moderate novel coronavirus infection. Monogravir Capsules are used for adult patients with mild to moderate disease and high risk factors for progression to severe disease within 5 days of onset. For severe patients, if the course of disease is short, especially if the nucleic acid load is high (Ct value <30), the above drugs can also be used.
media reports
Titanium Media Sina Sina 36Kr
Event Tracking
- 2023-01-13 The National Health Commission issued the “Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Version 4)”
- 2022-12-26 National Health and Medical Commission: New Coronary Pneumonia Renamed as Novel Coronavirus Infection, Implementing “Class B and B Control”
- 2022-03-15 Health and Medical Commission: Include two specific anti-new coronavirus drugs approved by the State Food and Drug Administration in the diagnosis and treatment plan
This article is transferred from: https://readhub.cn/topic/8my3e9b15oF
This site is only for collection, and the copyright belongs to the original author.